Statins Safety Signals: From Precautions to Proportionate Evidence-Based Labeling

The recent Cholesterol Treatment Trialists' Collaboration metaanalysis provides the most comprehensive randomized evidence to date regarding statin-associated adverse drug reactions, substantially narrowing the list of harms confidently attributable to statins. Beyond its clinical implications, the analysis highlights important challenges in pharmacovigilance and regulatory risk communication. Precautionary labeling based on low-certainty evidence may inadvertently amplify nocebo effects, reduce adherence to preventive therapies, and contribute to avoidable cardiovascular burden, particularly among vulnerable populations. We read the recent meta-analysis by the Cholesterol Treatment Trialists' (CTT) Collaboration, which provides the most comprehensive randomized evidence to date on adverse events attributed to statins. 1 By pooling individual participant data (> 120,000 participants) across 19 placebo-controlled trials, the authors demonstrated that the most commonly reported non-specific adverse drug reactions (ADRs) listed in the product labels, including cognitive impairment, depression, sleep disturbance, and peripheral neuropathy, did not occur with excess risk in statin vs. placebo groups. The CTT analysis confirms that only a limited number of adverse outcomes are supported by randomized